Results 271 to 280 of about 181,985 (340)

Bridging Pharmacokinetics and Pharmacodynamics: A PBPK/PD Model-Based Approach for Deferasirox Dosing in Transfusion-Dependent Thalassemia. [PDF]

Clin Transl Sci
Sakares W, Udomnilobol U, Pan X, Yampayon K, Ekwattanakit S, Viprakasit V, Limwongse C, Srichairatanakool S, Teerawonganan P, Kunsa-Ngiem S, Khaowroongrueng V, Techatanawat I, Prueksaritanont T, Yodsurang V.   +13 more
europepmc   +1 more source

Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites

, 1992
Ina Sungaila, William R. Bartle, Scott E. Walker, Carlo DeAngelis, Jack Uetrecht, Chris Pappas, E.I. Vidins   +6 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Pharmacogenomics of buprenorphine - a narrative review. [PDF]

Pharmacogenomics
Aravindan L, Velu S, Sivam I, Sivam S, Tallapaneni PS, Ressler R, Marks M, Venkataramanan R, Radhakrishnan R, Sadhasivam S.   +9 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Pharmacodynamics study of remimazolam besylate in anxious patients undergoing gastroscopy: a biased-coin design up-and-down sequential allocation trial. [PDF]

BMC Anesthesiol
Cha BZ, Hu SY, Chen NP, Cao JF, Xu C, Qiu K, Luo F.   +6 more
europepmc   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Correction to "Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction". [PDF]

Alzheimers Dement
europepmc   +1 more source

Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab. [PDF]

Front Pharmacol
Choi S, Park S, Jung J, Baek S, Lim HS.
europepmc   +1 more source